Medios Stock

Medios EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medios (ILM1.DE) as of Aug 8, 2026 is 41.73 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 62.95 M EUR — a change of -33.71% (lower).

EBITDA

41.73 MEUR

YoY

-33.71%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medios is 2026 41.73 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medios was 2025 62.95 M EUR. It decreases by -33.71% lower compared to the previous year.
Access this data via the Eulerpool API

Medios Stock analysis

What does Medios do? Medios AG is a leading company in the supply of high-quality specialty preparations to patients. The company was founded in Berlin in 2004 and has been listed on the Frankfurt Stock Exchange since 2018. Medios AG quickly achieved a strong position in the German healthcare market and currently employs approximately 300 employees at multiple locations in Germany. The business model of Medios AG is based on the production and distribution of high-quality specialty preparations. These are developed and produced in close collaboration with customers such as hospitals and outpatient clinics. Medios AG's products are typically used to treat rare and chronic diseases, such as immunological diseases, cancer, and metabolic disorders. Medios AG offers a wide range of products and services. The company is divided into three areas. The first area is Medios AG's core business, the distribution of specialty preparations. This area includes the development, production, and distribution of specialty preparations. The portfolio includes, for example, medications for pain and inflammation, as well as preparations for the treatment of Parkinson's and Alzheimer's diseases. Another important aspect in the field of specialty preparations is the supply of patients with parenteral nutrition solutions. These are used in both outpatient and inpatient settings to provide care for patients with severe diseases. The second area is supply services. Here, Medios offers a comprehensive range of services to support customers in hospital care and outpatient patient care. An important aspect of this area is the support of hospitals in dealing with delegations. For example, training is offered to educate hospital staff on the management of certain diseases. The third area is clinical study support. Medios AG offers services and products to support customers in clinical studies. The range includes criteria for patient-related logistics, the delivery of placebos and blinded medications, as well as specialty preparations and parenteral nutrition solutions. In each of these areas, Medios brings its high expertise and experience to develop the best possible solutions for customers and patients. Overall, Medios AG has established itself as an important partner for the German healthcare sector. The company pursues a clear strategy focused on the development and production of specialty preparations for the treatment of serious and rare diseases. The company places the highest value on the quality and safety of its products, as well as comprehensive consultation and customer care. Medios has a strong network of partners and suppliers in the healthcare industry and is a respected contact for customers and other market participants due to its experience and expertise. Medios is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medios stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medios is 41.73 M EUR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medios changed from 62.95 M EUR to 41.73 M EUR, representing a -33.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Medios since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Medios historically and in real time.

Access this data via the Eulerpool API

Income Statement — Medios

All Key Metrics — Medios